Policy | May 10, 2021
DCGI approves anti-COVID drug developed by DRDO
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
The facility is expected to be completed in 2024
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
Subscribe To Our Newsletter & Stay Updated
